Literature DB >> 2185345

Current strategies to reduce cisplatin toxicity.

A Sobrero1, A Guglielmi, C Aschele, R Rosso.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1990        PMID： 2185345     DOI： 10.1080/1120009x.1990.11738971

Source DB:  PubMed          Journal:  J Chemother        ISSN： 1120-009X            Impact factor:   1.714


× No keyword cloud information.
  7 in total

Review 1.  Guidelines for treatment of renal injury during cancer chemotherapy 2016.

Authors:  Shigeo Horie; Mototsugu Oya; Masaomi Nangaku; Yoshinari Yasuda; Yasuhiro Komatsu; Motoko Yanagita; Yuko Kitagawa; Hiroyuki Kuwano; Hiroyuki Nishiyama; Chikashi Ishioka; Hiromasa Takaishi; Hideki Shimodaira; Akira Mogi; Yuichi Ando; Koji Matsumoto; Daisuke Kadowaki; Satoru Muto
Journal:  Clin Exp Nephrol       Date:  2018-02       Impact factor: 2.801

Review 2.  Cisplatin-induced renal toxicity and toxicity-modulating strategies: a review.

Authors:  V Pinzani; F Bressolle; I J Haug; M Galtier; J P Blayac; P Balmès
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

3.  Preventive effect of 20 mEq and 8 mEq magnesium supplementation on cisplatin-induced nephrotoxicity: a propensity score-matched analysis.

Authors:  Takanori Miyoshi; Toshinobu Hayashi; Miyuki Uoi; Fuyuki Omura; Kyouichi Tsumagari; Sachi Maesaki; Chiaki Yokota; Takafumi Nakano; Takashi Egawa
Journal:  Support Care Cancer       Date:  2022-01-05       Impact factor: 3.603

4.  Cytotoxicity of Diimine Palladium (II) Complexes of Alkyldithiocarbamate Derivatives on Human Lung, Ovary and Liver Cells.

Authors:  Narges Aryanpour; Hassan Mansouri-Torshizi; Maryam Nakhjavan; Farshad H Shirazi
Journal:  Iran J Pharm Res       Date:  2012       Impact factor: 1.696

5.  Comparison of short and continuous hydration regimen in chemotherapy containing intermediate- to high-dose Cisplatin.

Authors:  Akira Ouchi; Masahiko Asano; Keiya Aono; Tetsuya Watanabe; Takehiro Kato
Journal:  J Oncol       Date:  2014-09-24       Impact factor: 4.375

6.  Oral rehydration solution (OS-1) as a substitute of intravenous hydration after cisplatin administration in patients with lung cancer: a prospective multicenter trial.

Authors:  Hidehito Horinouchi; Kaoru Kubota; Akihiko Miyanaga; Shinji Nakamichi; Masahiro Seike; Akihiko Gemma; Yuki Yamane; Futoshi Kurimoto; Hiroshi Sakai; Shintaro Kanda; Yutaka Fujiwara; Hiroshi Nokihara; Noboru Yamamoto; Tomohide Tamura; Yuichiro Ohe
Journal:  ESMO Open       Date:  2018-01-29

7.  Risk factors for cisplatin-induced acute kidney injury: A pilot study on the usefulness of genetic variants for predicting nephrotoxicity in clinical practice.

Authors:  Hiroyasu Oda; Toshiro Mizuno; Makoto Ikejiri; Maki Nakamura; Akira Tsunoda; Mikiya Ishihara; Kanako Saito; Satoshi Tamaru; Yoshiki Yamashita; Yuhei Nishimura; Kaname Nakatani; Naoyuki Katayama
Journal:  Mol Clin Oncol       Date:  2020-09-01
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.